Actavia Life Sciences, Inc.
RASP
$0.004
-$0.0285-87.69%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 255.00K | 4.15M | 4.15M | 4.10M | 4.16M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 345.20K | 4.24M | 4.24M | 4.22M | 4.25M |
| Operating Income | -345.20K | -4.24M | -4.24M | -4.22M | -4.25M |
| Income Before Tax | -406.60K | -4.44M | -4.44M | -4.44M | -4.98M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -0.41 | -4.44 | -4.44 | -4.44 | -4.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -406.60K | -4.44M | -4.44M | -4.44M | -4.98M |
| EBIT | -345.20K | -4.24M | -4.24M | -4.22M | -4.25M |
| EBITDA | -- | -- | -- | -30.90K | -158.70K |
| EPS Basic | 0.00 | -0.01 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | 0.00 | -0.01 | -0.01 | -0.01 | -0.02 |
| Normalized Diluted EPS | 0.00 | 0.00 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 3.09B | 2.90B | 2.31B | 1.72B | 1.08B |
| Average Diluted Shares Outstanding | 3.09B | 2.90B | 2.31B | 1.72B | 1.08B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
